NCT07315555Not yet recruiting
Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 18 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Tanta University
- Diseases
- Asthma
- NCT number
- NCT07315555
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Jan 2026 to the primary completion date, 1 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic corticosteroids within 4 weeks prior to enrollment
Other illness
- History of severe asthma exacerbation requiring ICU admission in the past 3 months
- Known hypersensitivity to Nigella sativa or its components
- Other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis)
- Significant comorbidities (e.g., cardiac, renal, or hepatic disorders)
Other
- Inability to comply with study procedures
Who the study is looking for
- Children aged 6-18 years
- Diagnosed with moderate persistent asthma according to the Global Initiative for Asthma (GINA) 2022 guidelines
- Receiving stable standard controller therapy (inhaled corticosteroids ± long-acting β2-agonists) for at least 4 weeks prior to enrollment
- Able to perform reproducible spirometry
Age in the registry: 6 years to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.